Market Place
Sourcing Support
Merck to Highlight Data at ESMO with Potential for Impact on Cancer Patients
07 Sep 2022 //
BUSINESSWIRE
Merck Europe B.V. Tepmetko(tepotinib) Receives Approval in Europe
05 May 2022 //
EMA
EC Approves TEPMETKO in Advanced NSCLC with METex14 Skipping Alterations
18 Feb 2022 //
BUSINESSWIRE
TEPMETKO Receives Positive CHMP Opinion in Advanced NSCLC
17 Dec 2021 //
BUSINESSWIRE
MHRA backs Merck’s MET inhibitor Tepmetko
13 Oct 2021 //
PHARMATIMES
EMD Serono to Highlights From Oncology Portfolio at WCLC & ESMO 2021
13 Sep 2021 //
BUSINESSWIRE
AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval
16 Aug 2021 //
GLOBENEWSWIRE
Merck’s MET inhibitor tepotinib gains positive opinion from MHRA
15 Jul 2021 //
PHARMATIMES
FDA Approves TEPMETKO® as the First and Only Once-daily Oral MET Inhibitor
03 Feb 2021 //
PRNEWSWIRE
FDA Approves TEPMETKO® as the First and Only Once-daily Oral MET Inhibitor
03 Feb 2021 //
PRNEWSWIRE
EU to review Merck`s targeted lung cancer drug
28 Nov 2020 //
PHARMATIMES
European Medicines Agency Validates Application for Tepotinib
26 Nov 2020 //
PHARMIWEB
Bexarotene combined with lapatinib for the treatment of Cushing’s disease
28 Aug 2020 //
NATURE
FDA starts quick review of Merck’s MET-targeting lung cancer drug
28 Aug 2020 //
PHARMAPHORUM
US FDA accepts Merck’s NDA for tepotinib and grants priority review status
26 Aug 2020 //
PHARMABIZ
FDA Accepts Filing of New Drug Application for Tepotinib for the Treatment
24 Aug 2020 //
PRNEWSWIRE
Novartis pulls ahead of Merck in MET-positive lung cancer race
11 Feb 2020 //
PMLIVE
Merck presented Data on Tepotinib for NSCLC at ESMO Asia 2019
27 Nov 2019 //
BIOSPECTRUM ASIA
Merck KGaA, Darmstadt, Germany, Announces Orphan Drug Designation for Tepotinib
19 Nov 2019 //
BIOSPACE
Merck KGaA touts FDA `breakthrough` status
12 Sep 2019 //
ENDPOINTS NEWS
MET inhibitors from Incyte/Novartis and Germany`s Merck face off
05 Jun 2019 //
ENDPTS
Merck KGaA, Darmstadt, Germany Provides Update on Tepotinib Phase II Results
11 Jun 2018 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.